Y-mAbs Announces Appointment of Gérard Ber to its Board of Directors and Planned Departure of Michael Buschle 11 December 2018
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical... Read more
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical... Read more
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical... Read more
NEW YORK, Oct. 23, 2018 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
Proceeds to fund Phase 2/3 trial of inhaled TD139 in idiopathic pulmonary fibrosis (IPF) and advancement... Read more
The Nordic countries have launched an ambitious plan to fast-track the development of a sustainable bioeconomy... Read more
NEW YORK, Sept. 20, 2018 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
Press Release: 17th September 2018 Today, BioPhero ApS has announced the closing of a seed investment... Read more
The FDA has granted Y-mAbs Breakthrough Therapy designation for naxitamab, in combination with GM-CSF,... Read more
Biotech and Money is an influential community of senior life science decision makers conducting impactful... Read more